Drugs / Anti ALPP CAR-T cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07123493 | Aug → Dec 2025 | — | Haifeng Qin | Terminated | No outcome recorded |
| Phase 0 | NCT07108140 | May → Dec 2025 | cancer | TCRCure Biopharma Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04627740 | Dec 2020 → Feb 2025 | cancer | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-ALPP CAR-T cells | “after infusion with anti-ALPP CAR-T cells.” NCT04627740 ↗ |
| Modality | Cell therapy | “anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells” NCT04627740 ↗ |
| Target | ALPP | “anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells” NCT04627740 ↗ |